Compare Agilent Technologies Inc (A) vs Brown-Forman Corporation Class B (BF.B) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Agilent Technologies Inc vs Brown-Forman Corporation Class B — how do they compare? Agilent Technologies Inc trades at $128.92 (market cap $37.04B), while Brown-Forman Corporation Class B trades at $25.88. The key difference: Agilent Technologies Inc pays a 0.78% dividend while Brown-Forman Corporation Class B pays none. Which is the better fit depends on your goals.
| A | BF.B | |
|---|---|---|
Market Cap | $37.04B | — |
Sector | Health | Consumer Staples |
52-Week High | $157.20 | $31.26 |
52-Week Low | $110.24 | $22.80 |
Enterprise Value | $38.59B | — |
Dividend Yield | 0.78% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $131.14, up 0.34% on the day, with a bearish technical signal but strong analyst support. The stock shows solid profitability with a net margin of 19.55% and ROE of 21.33%, supported by recent earnings beats. Recent acquisitions like Biocare Medical highlight growth initiatives, while cash flow trends remain positive. Valuation ratios such as P/E of 26.22 are elevated but align with quality growth expectations.
The outlook is positive given analyst consensus with a $154.90 price target and 77.5% buy ratings. Risks include execution of acquisitions and macroeconomic pressures on life sciences spending. The stock offers growth potential from AI-driven product launches, though technical resistance near $132 may cap near-term gains.
BF.B trades at $25.91, down 0.92% on the day, with a bearish technical outlook per moving averages. Recent earnings show three beats out of four quarters, with Q2 2024 EPS of $0.48 beating the $0.46 estimate. Analyst consensus is mixed, with 25% buy, 50% hold, and 25% sell ratings.
The stock faces near-term pressure from technical weakness, but earnings resilience offers fundamental support. Risks include execution challenges and market sentiment shifts. Upside depends on sustained earnings outperformance and positive analyst revisions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About Brown-Forman Corporation Class B
Brown-Forman is the largest U.S.-domiciled producer of distilled spirits. The firm reports only a single operating segment, and whiskey represents its primary business driver, generating roughly three-quarters of sales, undergirded by the Jack Daniel's brand as well as bourbons such as Woodford Reserve and Old Forrester. Notable nonwhiskey offerings include tequilas such as el Jimador and Herradura. The firm operates globally, with products sold in more than 170 countries, and adapts its route-to-consumer model depending on regulation as well as the prevailing competitive dynamics in a given market. For example, it sells through distributors in the U.S. but operates its own logistics apparatus in many other countries. The company remains under the control of the Brown family.
Read more on BF.B →
